- Home
- BMEA vs PEPG Comparison
BMEA vs PEPG Comparison
Compare BMEA & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- PEPG
- Stock Information
- Founded
- BMEA 2017
- PEPG 2018
- Country
- BMEA United States
- PEPG United States
- Employees
- BMEA N/A
- PEPG N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- PEPG Health Care
- Exchange
- BMEA Nasdaq
- PEPG Nasdaq
- Market Cap
- BMEA 275.6M
- PEPG 292.3M
- IPO Year
- BMEA 2021
- PEPG 2022
- Fundamental
- Price
- BMEA $11.24
- PEPG $8.72
- Analyst Decision
- BMEA Buy
- PEPG Strong Buy
- Analyst Count
- BMEA 13
- PEPG 2
- Target Price
- BMEA $36.33
- PEPG $23.00
- AVG Volume (30 Days)
- BMEA 1.1M
- PEPG 83.8K
- Earning Date
- BMEA 11-01-2024
- PEPG 11-06-2024
- Dividend Yield
- BMEA N/A
- PEPG N/A
- EPS Growth
- BMEA N/A
- PEPG N/A
- EPS
- BMEA N/A
- PEPG N/A
- Revenue
- BMEA N/A
- PEPG N/A
- Revenue This Year
- BMEA N/A
- PEPG N/A
- Revenue Next Year
- BMEA N/A
- PEPG N/A
- P/E Ratio
- BMEA N/A
- PEPG N/A
- Revenue Growth
- BMEA N/A
- PEPG N/A
- 52 Week Low
- BMEA $3.61
- PEPG $3.72
- 52 Week High
- BMEA $22.74
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- BMEA 64.18
- PEPG 43.18
- Support Level
- BMEA $10.35
- PEPG $8.54
- Resistance Level
- BMEA $12.30
- PEPG $9.15
- Average True Range (ATR)
- BMEA 0.93
- PEPG 0.50
- MACD
- BMEA -0.01
- PEPG 0.02
- Stochastic Oscillator
- BMEA 47.26
- PEPG 18.95
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.